The Parkinson s Disease Composite Scale

Similar documents
Motor symptoms: Tremor: Score (total of four limbs) Absent 0 Symptom not present

U n i f i e d P a r k i n s o n s D i s e a s e R a t i n g S c a l e ( U P D R S )

Unified Parkinson Disease Rating Scale (UPDRS)

Form B3L: UPDRS Part III Motor Examination 1

ID # COMPLETED: YES.. 1 DATE NO... 5 NEUROLOGICAL EXAM

Non-Motor Symptoms of Parkinson s Disease

Parkinson s Diseasee

Unified Parkinson's Disease Rating Scale UPDRS

Issues for Patient Discussion

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Multiple choice questions: ANSWERS

Optimizing Clinical Communication in Parkinson s Disease:

Data Collection Worksheets

Evaluation of Parkinson s Patients and Primary Care Providers

Unified Parkinson's Disease Rating Scale UPDRS

Prior Authorization with Quantity Limit Program Summary

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

2. Multi-domain scales

Parkinson s Disease. Sirilak yimcharoen

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

10th Medicine Review Course st July Prakash Kumar

III./3.1. Movement disorders with akinetic rigid symptoms

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

Common Forms of Dementia Handout Package

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Parkinson s Disease and other related movement disorders a video guide to diagnosis

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

The PD You Don t See: Cognitive and Non-motor Symptoms

An Approach to Patients with Movement Disorders

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Joint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD

Pantothenate Kinase Associated Neurodegeneration Disease Rating Scale (PKAN-DRS)

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM

UNC CFAR Social and Behavioral Science Research Core SABI Database

The Fresco Institute for Parkinson's and Movement Disorders

Deep Brain Stimulation: Indications and Ethical Applications

PARKINSON S DISEASE MEDICAL ASSESSMENT FORM FOR SOCIAL SECURITY DISABILITY APPLICATION

Dementia: How to explain the diagnosis to patients and relatives

PARKINSON S DISEASE 馬 萬 里. Chinese character for longevity (shou) Giovanni Maciocia

Presented by Joanna O Leary, MD Providence St. Vincent Medical Center Movement Disorder Department

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

Alison Charleston 1 st September 2016

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Differential Diagnosis of Hypokinetic Movement Disorders

Drugs used in Parkinsonism

Treatment of Parkinson s Disease: Present and Future

Very few seniors contemplated suicide. The mortality rate for suicide among seniors decreased in both Peel and Ontario between 1986 and 2001.

Aging and Mental Health Current Challenges in Long Term Care

P20.2. Characteristics of different types of dementia and challenges for the clinician

10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Tremor 101. Objectives 9/30/2015. Importance of tremors

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Mastering Your Anxiety in Parkinson s Disease

PD AND FALLS J U MALLYA FALLS AWARENESS MEETING

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

Appendix N: Research recommendations

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

CAREGIVER SUMMIT. The PD You Can't See: Dealing with Non-Motor Symptoms. Kaitlyn Roland, PhD. Sponsored by:

Movement Disorders- Parkinson s Disease. Fahed Saada, MD March 8 th, th Family Medicine Refresher Course St.

Health of the Nation Outcome Scales 65+ Glossary

SPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS WELCOME AND INTRODUCTIONS

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

Caregiving for an Individual with Dementia: Beginning the Journey

Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Enhanced Primary Care Pathway: Parkinson s Disease

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Dr Barry Snow. Neurologist Auckland District Health Board

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s Disease Current Treatment Options

SIMPSON-ANGUS SCALE (SAS)

Patient Re-Examination Form

A tabulated glossary for use with HoNOS 65+

Residual Functional Capacity Questionnaire PARKINSON S DISEASE

Apathy, fatigue and quality of life in patients with Parkinson's disease Skorvanek, Matej

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Residual Functional Capacity Questionnaire MULTIPLE SCLEROSIS

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Package leaflet: Information for the user

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

IMPAIRMENT OF THE NERVOUS SYSTEM

SHAKING UP THE WORLD OF PARKINSON S DISEASE

What is Parkinson s Disease?

Headway Victoria Epilepsy and Parkinson s Centre

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

Individual Planning: A Treatment Plan Overview for Individuals Sleep Disorder Problems.

4. Pertinent physical findings including: a. Results of tests performed on patient, including dates and specific findings:

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y

Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine)

Evolution of a concept: Apraxia/higher level gait disorder. ataxia v. apraxia gait = limb apraxia. low, middle, high gait disturbance levels

Transcription:

The Parkinson s Disease Composite Scale Motor symptoms Bradykinesia: (Total of finger tapping, alternating hand movements, legs agility, total impression of body bradykinesia) Mild 1 Minimal slowness, giving movement a deliberate character; could be normal for some persons. Possibly reduced amplitude. Moderate 2 Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, some reduced amplitude. Moderate slowness, poverty or small amplitude of movement. Very severe 4 Marked slowness, poverty or small amplitude of movement. Tremor: (Total of four limbs) Mild 1 Slight and infrequently present. Moderate 2 Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present. Moderate in amplitude and present most of the time. Very severe 4 Marked in amplitude and present most of the time. Gait: Mild 1 Walks slowly, may shuffle with short steps, no festination or propulsion. Moderate 2 Walks with difficulty, little or no assistance, some festination, short steps or propulsion. Severe disturbance, frequent assistance. Very severe 4 Cannot walk. 1 epda.eu.com

Balance/postural stability: Mild 1 Walks without help, recovers unaided at pull test. Moderate 2 Walks with help, would fall if not caught at pull test. Walks with help, falls spontaneously at pull test. Very severe 4 Wheelchair bound, unable to stand. Freezing: Mild 1 1-2 seconds very rarely. Moderate 2 3-10 seconds rarely. 11-30 seconds often. Very severe 4 31 seconds always. Nocturnal akinesia: Mild 1 Mild loss of the ability to move (10-20% of the night). Moderate 2 Moderate loss of the ability to move (21-40% of the night). Severe loss of the ability to move (41-60% of the night). Very severe 4 Very severe loss of the ability to move (61-100% of the night). Non-motor symptoms (in the past 2 weeks) Fatigue: Mild 1 Fatigue interferes very rarely with physical functioning/carrying out duties/responsibilities. Moderate 2 Fatigue interferes rarely with physical functioning/carrying out duties/responsibilities. Fatigue interferes often with physical functioning/carrying out duties/responsibilities. Very severe 4 Fatigue interferes always with physical functioning/carrying out duties/responsibilities. Urinary: Mild 1 Very rarely urgency and frequency day/night. Moderate 2 Rarely urgency and frequency day/night. Often urgency and frequency day/night, rarely loss of urine. Very severe 4 Always urgency and frequency day/night, frequent loss of urine. 2 epda.eu.com

Cognitive impairment: Mild 1 Occasional forgetfulness with partial recollection of events and no other difficulties. Moderate 2 Very severe 4 Moderate memory loss, with disorientation and moderate difficulty handling complex problems. Mild but definite impairment of function at home with need of occasional prompting. Severe memory loss with disorientation for time and often to place. Severe impairment in handling problems. Severe memory loss with severe spatio-temporal disorientation. Unable to make judgments or solve problems. Requires much help with personal care. Cannot be left alone at all. Depression/anxiety: Mild 1 Periods of sadness or anxiety greater than normal, never sustained for days or weeks. Moderate 2 Sustained depression or anxiety (1 week or more). Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss of interest) or sustained anxiety. Very severe 4 Sustained depression with vegetative symptoms and suicidal thoughts or intent. Symptomatic orthostatic hypotension: Mild 1 Very rare dizziness/high headedness/feeling faint/generalised weakness. Moderate 2 Rare dizziness/high headedness/feeling faint/generalised weakness. Very severe 4 Often dizziness/high headedness/feeling faint/generalised weakness and occasional loss of consciousness. Always dizziness/high headedness/feeling faint/generalised weakness and frequent loss of consciousness. 3 epda.eu.com

Hallucinations or thought disorder (due to drug intoxication or dementia): Mild 1 Vivid dreaming or hallucinations. Moderate 2 Benign hallucinations with insight retained. Occasional to frequent hallucinations or delusions; without insight; could interfere with daily activities. Very severe 4 Persistent hallucinations, delusions or florid psychosis. Not able to care for self. Treatment complications: (in the past 2 weeks) Dyskinesia: (or if present, rate the severity of camptocormia and/or Pisa syndrome) Mild 1 Dyskinesia present 25% of on-time, or more but not interfering with daily activities. Moderate 2 Dyskinesia present 26-50% of on-time, mildly interfering with daily activities. Dyskinesia present 51-75% of on-time, or less but interfering with daily activities. Very severe 4 Dyskinesia present 76% of on-time and interfering with daily activities. Dystonia: Mild 1 Dystonia present less than 30 minutes a day. Moderate 2 Dystonia present less than 60 minutes a day. Dystonia present less than 2 hours a day, with pain. Very severe 4 Dystonia present more than 2 hours a day, with severe pain. ON/OFF: Mild 1 Time spent in the OFF state: 25% of waking day; fluctuations impact on a few activities. Moderate 2 Time spent in the OFF state: 26-50% of waking day; fluctuations impact on some activities. Time spent in the OFF state: 51-75% of waking day; fluctuations impact on many activities. Very severe 4 Time spent in the OFF state: 76% of waking day; fluctuations impact on all the activities. 4 epda.eu.com

Dopamine dysregulation syndrome: Absent 0 Symptom not present Mild 1 Very rare auto-medication/mood disturbance/violent behaviour/compulsive behaviour. Moderate 2 Rare auto-medication/mood disturbance/violent behaviour/compulsive behaviour. Often auto-medication/mood disturbance/violent behaviour/compulsive behaviour. Very severe 4 Always auto-medication/mood disturbance/violent behaviour/compulsive behaviour. Disability level: Absent 0 Able to perform daily activity without problems. Mild 1 Limitations to perform exigent or instrumental daily activities. Moderate 2 Limitations to perform basic daily activities. Needs help to perform some basic daily activities. Very severe 4 Dependent of other persons to perform all basic daily activities. If you are a healthcare professional and you have used the Parkinson s Disease Composite Scale (PDCS), we would kindly ask you to complete a short survey here: www.surveymonkey.com/r/pdcsfeedback The answers to this survey will provide the European Parkinson s Disease Association (EPDA) with valuable feedback which will be used to further develop the PDCS. 5 epda.eu.com